Physician profile

Nagarajan Devar

Internal Medicine · Venice, FL

NPI 1366491995

$1,357.11

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $192.64 2019-2020
Amgen INC. $161.02 2019-2021
Lilly USA, LLC $131.95 2019
Pfizer INC. $98.41 2019-2021
Kowa Pharmaceuticals America, INC. $82.56 2019-2021
Merck Sharp & Dohme LLC $76.98 2019-2021
Astellas Pharma US INC $72.09 2019-2020
Novo Nordisk INC $69.10 2020-2021
Amarin Pharma, INC. $69.10 2019-2021
Janssen Pharmaceuticals, INC $57.04 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $50.54 2020-2021
Grt US Holding, INC. $49.09 2021
Ibsa Pharma INC. $46.00 2020
Novartis Pharmaceuticals Corporation $40.76 2019
Astrazeneca Pharmaceuticals Lp $38.13 2019-2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Radius Health, INC. $28.05 2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $24.04 2020
Allergan, INC. $21.34 2020
Sunovion Pharmaceuticals INC. $19.63 2021
Eisai INC. $14.97 2020
Biohaven Pharmaceuticals, INC. $13.67 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nagarajan Devar

$1,357.11

in general payments reported 2019-2025

Years
2019-2021
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/1000233/nagarajan-devar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.